TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

计划入组 90 人 · 首次发布于 2023 年 8 月 21 日

Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer

计划入组 249 人 · 首次发布于 2026 年 1 月 5 日

Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer

计划入组 109 人 · 首次发布于 2024 年 5 月 1 日

HER2+ Breast Cancer(Diakonos)

oncology program (HER2+ breast cancer)

CDK2 inhibitor (ER+/HER2- breast cancer)

JAPAN BREAST CANCER RESEARCH GROUP

Japan

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

International Breast Cancer Research Foundation

United States

MammaPrint Genomic Profiling Predicts Anthracycline Benefit in HR+HER2- Early Breast Cancer, Guiding NCCN Guideline Update

Lasofoxifene Shows Early Activity in HR+/HER2- Breast Cancer via Ki-67 Suppression

Kisqali Demonstrates Sustained Benefit in Early Breast Cancer